Cellscreen Of Australia Plans To Take HPV Test Global
This article was originally published in PharmAsia News
Executive Summary
Australia's Cellscreen Direct plans to market its Tam-Pap test for the human papilloma virus in a global market it deems to be worth $4 billion. The home test for HPV was approved by the Therapeutics Goods Administration last year to join a vaccine and the pap smear test on the Australian market. Cellscreen said that by raising the funds to go global, it expected to raise the current 60 percent rate for screening, attracting some of the many women uncomfortable with the pap smear. The Australian firm already has applied with the U.S. FDA and expects to seek EU approval early next year. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.